ArticleScience China. Life sciences2026
ZO-1-dependent fibrotic scar border formation impedes axon regeneration after spinal cord injury.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrotic scarring acutely corrals inflammation but chronically impedes axon regeneration via dense border structures after spinal cord injury (SCI). Although the origin and heterogeneity of fibroblasts have been extensively studied, effective strategies to prevent fibrotic scarring, especially the formation of its border structure, remain elusive. Here, we identified a distinct fibroblast subpopulation with markedly upregulated tight junction protein 1 (ZO-1) expression, which contributes to the formation of fibrotic scar borders after SCI. While ZO-1 has been conventionally considered restricted to epithelial/endothelial cells, our data may indicate a novel role in the formation of fibrotic scar border by platelet-derived growth factor receptor beta (PDGFRβ)-positive fibroblasts. Genetic ablation of Tjp1 (encoding ZO-1) in fibroblasts disrupted the fibrotic scar border, allowing serotonergic and tyrosine hydroxylase axons to grow into the lesion core after SCI. Disruption of the fibrotic scar border induced by ZO-1 knockout did not exacerbate inflammatory spread or damage residual neurons after SCI. Furthermore, PDGFB/PDGFRβ pathway activation induced ZO-1 expression and scar border formation in the intact spinal cord, whereas its inhibition suppressed ZO-1 upregulation and disrupted the scar border after SCI. Remarkably, combined targeting of PDGFRβ (using SU16f) and ZO-1 function (via LAT-A) synergistically promoted axonal growth across the lesion. Our findings identify ZO-1 as a critical orchestrator of the fibrotic scar border and reveal a combined therapeutic approach for enhancing axon regeneration after SCI.
Indexed as
Identifiers
42616294What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.